Dual or single immunotherapy with chemotherapy improves esophagus cancer survival
Patients with advanced esophageal squamous cell carcinoma (ESCC) who receive either one or two checkpoint inhibitors along with chemotherapy have significantly improved overall survival than from chemotherapy alone.